Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer
Jianxin Chen,Qinhong Zheng,Junhui Wang,Xueli Zhang,Yingguo Lv
DOI: https://doi.org/10.1097/md.0000000000036959
IF: 1.6
2024-02-25
Medicine
Abstract:SMARCA4 (SWI/SNF-related, matrix-associated, actin dependent regulator of chromatin, subfamily A), an oncogene located at 19p13.2 and encodes the BRG1 protein, is one of the important subunits of SWI/SNF chromatin remodeling complex, which has been considered as a powerful regulator of transcription and DNA repairing, thereby plays an important role in cell cycle control and cell differentiation. [ 1 ] The inactivation of SMARCA4 protein usually leads to a loss of the function of the subunit in SWI/SNF complex and the interruption of ATP energy supply, thus affecting the repositioning or remodeling of the nucleosome of the complex. Transcription cannot be progressed due to the lacking of access to the DNA region that needs to be transcribed, and finally result in the occurrence and progression of various cancer types. [ 2–4 ] SMARCA4 is a novel oncogene that has been reported and named in recent years. In 2015, Le Loarer et al reported a type of highly aggressive thoracic sarcomas, which occurring in young male patients, along with undifferentiated immunophenotype and SMARCA4 loss, and usually presented as an extremely aggressive clinical course and named it as SMARCA4-deficient thoracic sarcoma. [ 5 ] In 2021, the new WHO Classification of Tumors of the Lung, Pleura, Thymus, and Heart adopted the term "SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT)" for the group of tumors that has been previously described as SMARCA4-dTS, which is considered a separate entity from SMARCA4-deficient non-small cell lung cancer (NSCLC). [ 6 ] SMARCA4 mutations has been reported in a variety of cancer types, including uterine sarcoma, small cell carcinoma of the ovary with hypercalcemia, undifferentiated carcinoma of the nasal cavity/sinuses, pleomorphic carcinoma of the gastrointestinal tract, Burkitt lymphoma, and approximately 5% of NSCLC. [ 7 ] It has been reported that patients diagnosed as NSCLC harboring SMARCA4-deficient presented with the characteristics including absence of targetable sensitive mutations, primary resistant to various cytotoxic drugs, and thereby leading to poor prognosis. [ 8 , 9 ] The largest retrospective study which screened 2689 patients with NSCLC for SMARCA4 mutations, conducted in Dana-Farber Cancer Institute has reported that patients with SWI/SNF-mutant NSCLCs had a statistically lower prevalence of concurrent targetable driver mutations ( P < .001), and a significantly shorter median overall survival (mOS) from the time of advanced disease diagnosis ( P = .01), when comparing to SWI/SNF wild-type NSCLC. [ 10 ] Among the 555 SWI/SWF-mutated tumors in that research, the most frequently co-altered genes were presented as TP53, KRAS, and STK11.
medicine, general & internal